pcDNA3-AU1-mTOR-S2215Y Citations (3)

Originally described in: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.
Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F Oncogene. 2010 May 6. 29(18):2746-52. PubMed Journal

---

Articles Citing pcDNA3-AU1-mTOR-S2215Y

Articles
Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. Havel JJ, Li Z, Cheng D, Peng J, Fu H. Oncogene. 2015 Mar 19;34(12):1487-98. doi: 10.1038/onc.2014.91. Epub 2014 Apr 7. PubMed
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH. Nat Cell Biol. 2016 Jun;18(6):632-44. doi: 10.1038/ncb3355. Epub 2016 May 16. PubMed
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA. Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014. PubMed

If you have published an article using this material, please email us at to have your article added to this page.